

TRIS AMINO[®] TRIS AMINO[®]·HCl

Both come from Brae Labs, so each represents the highest purity reagent grade available. Virtually devoid of heavy metals.

And now you can get both in laboratory quantities!

The usefulness of TRIS AMINO* as an effective buffer in sensitive biochemical

reactions is well known.

So compare Brae purity with products you've used in the past. We think you'll like the results... and the price.

But to prove it, you'll need a supply. So contact us now for a free sample, specifications and complete information.



Brae Laboratories, Inc.
230 Centre St.
Nutley, N.J. 07110
(201) 661-1061

*A brand of tris (hydroxymethyl) aminomethane


Circle No. 26 on Readers' Service Card

MINIATURE INERT VALVES

Inert valves for ultra-pure or corrosive fluids. Wide variety of styles and sizes, leak-tight, chemically inert...for panel mounts, table mounts, or free standing systems.

Free Catalog...write to
Hamilton Company,
P.O. Box 10030,
Reno, Nevada 89510.

HAMILTON



Circle No. 190 on Readers' Service Card

LETTERS

The LDH Virus: An Interfering Biological Contaminant

The lactate dehydrogenase-elevating virus (LDH virus) is widely distributed in nature, having been found in wild and laboratory mice in North America, Australia, England, and Europe (1-4).

Of special relevance to the biological research community is the inconspicuous and thus unappreciated presence of this "silent" virus in many of the mouse-passaged materials used in biomedical research. Known contaminations have occurred in more than 100 transplantable mouse tumors, many of the oncogenic virus preparations, and other viral, bacterial, and *Bartonella*-like materials that have been or are being serially passed in mice (1-4).

We wish to call attention to the interpretative hazards associated with the wide variety of physiological alterations that this ubiquitous agent is capable of inducing in experimental mice. Some of the host alterations that are known to be associated with this viral infection have been erroneously ascribed to implanted tumors, oncogenic viruses, or to other experimentally imposed factors or conditions. Thus, certain immunological changes or manifestations observed in mice after tumor transplants or inoculation with other oncogenic materials may result, either largely or in part, from the concomitant LDH viral infection. The presence of the LDH virus is therefore capable of modifying and compromising otherwise carefully acquired biological data.

Following is an abridged list of host alterations and influences that are associated with the LDH viral infection and have caused or are capable of causing distortion, misinterpretation, or confusion of experimental data:

1) Immunological effects: lymphocyte trapping; thymus involution; changes in T cells, B cells, and macrophages; moderate splenomegalia and lymph node enlargement; enhancement or depression of humoral immunity; depression of cellular immunity; and production of virus-antibody complexes (1-6).

2) Endocrinological alterations: two- to tenfold increases in plasma corticosterone levels during the acute phase of viral infection (1, 6, 7).

3) Host enzyme changes: two- to hundredfold increases in plasma LDH and some other plasma enzymes, some of lifelong persistence (1-4).

4) Modifications of cancer therapy: potentiation of asparaginase and glutaminase effectiveness (8).

5) Alterations of host clearance capabilities: decreases in the rate of clearance of many naturally occurring or injected enzymes and other proteins and two- to tenfold increases in their half-life (9).

6) Changes in tumor behavior: increases in the incidence and growth rates of certain tumors and reduction of the percentage of regressions and of host survival times (6, 10).

7) Alterations in oncogenic viral expression: increases in tumor incidence; reduction of spontaneous regressions; increases in the number of spleen foci; and production of interferon (6, 11). Suppression of the incidence of mouse mammary tumor viruses or of tumors induced by the Moloney sarcoma virus under special conditions (12).

Investigators working with biological materials that have a high probability of carrying this silent virus are urged to establish its presence or absence. Editors and reviewers charged with monitoring the accuracy of published material should challenge submitted manuscripts that are appropriately suspect. As a minimum, the presence or absence of the virus in recipient mice and in mouse-passaged preparations should be clearly stated in all reports of research in which such materials were used.

However, to cope most effectively with this problem, it is also necessary to remove the passager LDH virus, when present, from the classical, as well as newer, transplantable mouse tumors, from oncogenic and other virus preparations, and from miscellaneous mouse-passaged materials such as experimental murine pathogens and *Eperythrozoon coccoides*. Protective housing, quarantine procedures, and appropriate sanitary safeguards should also be used to prevent uncontrolled reinfection (12, 13).

The LDH virus produces a lifelong persisting viremia in infected animals. There is no known therapeutic means capable of eliminating the virus from the host. It is possible, however, by utilizing either special tissue culture techniques or appropriate heterotransplantation procedures to delete the LDH virus from specific tumors, mouse-passaged bacterial and viral materials, or other contaminated preparations, and then to transplant such virus-free materials back into "clean" mice (2, 4).

While it is possible for each laboratory to test and "purify" their own contaminated preparations, in practice this is time-consuming and requires special expertise and appropriate research facilities. Since LDH viral contamination will be a continuing problem for the foreseeable future because of recontaminations, individual solutions to the problem



From tissue to homogenate in 30 seconds!

For homogenization, dispersion, defibrillation and emulsification, nothing works quite like a Polytron. Utilizing the Willers "High Frequency Principle", the Polytron combines ultrasonic energy with mechanical shearing action to homogenize virtually any type of tissue . . . small organs, soft bones, muscle, cartilage, even an entire mouse.

Because of its unique shearing effect, the Polytron outperforms any blender, mixer or similar homogenizer, and requires only 30-60 seconds to do what other instruments do in 15 minutes or more. This rapid action is an important advantage when working with heat-sensitive biological materials.

The Polytron system offers a wide selection of models, generators and speeds to provide ideal conditions for homogenization as dictated by type of material, experimental conditions and desired end result. For an informative brochure, write: Polytron Division, Brinkmann Instruments, Cantiague Road, Westbury, N.Y. 11590. In Canada: 50 Galaxy Boulevard, Rexdale (Toronto), Ont.

Brinkmann Polytron®

EMI

EMI 9789QB
PHOTOMULTIPLIERS



FOR
MEASUREMENTS
AT THE LOWEST
LIGHT LEVELS

For D.C. or pulse counting applications where only a small number of photons are available, EMI offers the 9789 Photomultiplier with a 10mm high efficiency bialkali cathode and a unique front end geometry. This tube typically operates at 1350 V overall for 4×10^7 gain with a corresponding dark current of 10^{-10} A at 20°C. Total dark counts are typically 50 counts/sec. at 20°C with a further reduction to 10 counts/sec. at -20°C. The 9789 is available with a quartz (fused silica) window as the 9789QB or with a pyrex window as the 9789B. The 9789 is a direct plug in replacement for the well known 6256/9502.



Detailed data from:
EMI GENCOM INC.
 80 Express St.
 Plainview, New York 11803
 Tel (516) 433-5900
 TWX 510-221-1889

are not consistent with realistic research economics. Such a special technical need of a significant section of the biological and biomedical research community could be more effectively accomplished by establishing a central laboratory within or sponsored by the National Institutes of Health or an appropriate institute or foundation. The establishment of such a center for both the detection and elimination of the virus would provide greater assurance that costly research studies in which mice are used would not be subject to misinterpretation as a consequence of the presence of an uncontrolled agent that alters immunological and other basic physiological parameters.

VERNON RILEY

DARREL H. SPACKMAN

GEORGE A. SANTISTEBAN

Pacific Northwest Research Foundation and Fred Hutchinson Cancer Research Center, Seattle, Washington 98104

GILBERT DALLDORF

Oxford, Maryland 21654

INGEGERD HELLSTROM

KARL-ERIC HELLSTROM

Fred Hutchinson Cancer Research Center

EUGENE M. LANCE

Cancer Center of Hawaii, University of Hawaii at Manoa, Honolulu 96822

K. E. K. ROWSON

University of London, London WC1 8EE, England

B. W. J. MAHY

University of Cambridge, Cambridge CB2 2QQ, England

PETER ALEXANDER

Royal Cancer Hospital, Belmont, Sutton, Surrey, England

C. CHESTER STOCK

Memorial Sloan-Kettering Cancer Center, New York 10021

HANS O. SJÖGREN

Department of Medical Microbiology, University of Lund, Lund, Sweden

VINCENT P. HOLLANDER

Research Institute for Skeletomuscular Disease, Hospital for Joint Diseases, New York 10035

M. C. HORZINEK

Instituut voor Virologie, Faculteit der Diergeneeskunde, Rijksuniversiteit te Utrecht, Utrecht, Netherlands

References

1. V. Riley, *Prog. Med. Virol.* **18**, 198 (1974).
2. ———, in *Busch Methods in Cancer Research* (Academic Press, New York, 1968), vol. 4, pp. 493–618.
3. ———, F. Lilly, E. Huerto, D. Bardell, *Science* **132**, 545 (1960); A. L. Notkins, *Bacteriol. Rev.* **29**, 143 (1965).
4. K. E. D. Rowson and B. W. J. Mahy, in *Lactic Dehydrogenase Virus*, S. Gard and C. Hallaver, Eds. (Virology Monograph 13, Springer-Verlag, New York, 1975).
5. M. B. A. Oldstone and F. J. Dixon, *J. Immunol.* **106**, 1260 (1971); A. L. Notkins, S. Mahar, C. Scheele, J. Goffman, *J. Exp. Med.* **124**, 81 (1966); S. E. Mergenhagen, A. L. Notkins, S. F. Dougherty, *J. Immunol.* **99**, 578 (1967); K. E. K. Rowson and B. W. J. Mahy, *J. Gen. Microbiol.* **39**, xi (1965); M. J. Snodgrass and M. G. Hanna, Jr., *J. Nat. Cancer Inst.* **45**, 741 (1970); R. J. Howard, A. L. Notkins, S. E. Mergenhagen, *Nature (London)* **221**, 873 (1967); V. Riley, W. Braun, M. Ishizuka, D. Spackman, *Proc. Natl. Acad. Sci. U.S.A.* **73**, 1707 (1976).
6. V. Riley and D. Spackman, in *Modulation of Host Immune Resistance in the Prevention or Treatment of Induced Neoplasias*, M. A. Chirigos, Ed. (Government Printing Office, Washington, D.C., 1977), pp. 319–336.
7. D. Spackman and V. Riley, *Proc. Am. Assoc. Cancer Res.* **16**, 170 (1975); G. A. Santisteban, V. Riley, M. A. Fitzmaurice, *Proc. Soc. Exp. Biol. Med.* **139**, 202 (1972).
8. V. Riley, *Nature (London)* **220**, 1245 (1969); D. Spackman and V. Riley, *Proc. Am. Assoc. Cancer Res.* **14**, 113 (1973); V. Riley, *Pathol. Biol.* **18**, 757 (1970); ———, D. Spackman, M. A. Fitzmaurice, J. Roberts, J. S. Holcenberg, W. C. Dolowy, *Cancer Res.* **34**, 429 (1974); V. Riley, H. A. Campbell, C. C. Stock, *Proc. Soc. Exp. Biol. Med.* **133**, 38 (1970).
9. V. Riley, J. D. Loveless, M. A. Fitzmaurice, W. M. Siler, *Life Sci.* **4**, 487 (1965); A. L. Notkins and C. Scheele, *J. Nat. Cancer Inst.* **33**, 741 (1964).
10. V. Riley and D. Spackman, in *The Pigment Cell; Melanomas: Basic Properties and Clinical Behavior*, V. Riley, Ed. (Karger, Basel, 1976), pp. 163–173.
11. W. Turner, P. S. Ebert, R. Bassin, G. Spahn, M. A. Chirigos, *Proc. Soc. Exp. Biol. Med.* **136**, 1314 (1971); R. Evans and V. Riley, *J. Gen. Virol.* **3**, 449 (1968).
12. V. Riley, *Science* **153**, 1657 (1966).
13. ——— and D. Spackman, *Lab. Anim.* **6**, 16 (1977).

Xeroxing Life

Barbara J. Culliton's excellent summary of the burgeoning controversy over human cloning (News and Comment, 24 Mar., p. 1314) suggests that once it is full-blown, this one will be dominated by arguments even more specious than those advanced (on both sides) by recombinant DNA research extremists. I am concerned here with only one of the possibilities: doubtless there will be opportunity in the future for ventilation of the others. At issue is the false notion, thus far undisputed by scientists responding to the press, that the product of a single successful nuclear transplantation is a "clone," that is, an *identical copy* (I avoid Jeremy Rifkin's plug for Xerox) of the individual donating the transplanted nucleus. My concern with this specific point is that, more than any other, the idea of mass production of identical persons is repugnant to the laity, perhaps because it is so obvious a departure from the organic way of doing things.

There is, however, no possibility in principle of making copies identical to an individual donor by the method being discussed. All animal ova studied so far, including those of mammals, contain a population of "maternal" messenger RNA molecules, laid down in the egg cytoplasm during oogenesis, and functioning in protein synthesis during development proper (1, 2). Protein synthesis is indispensable for development, and a